$ARTV

RA CAPITAL MANAGEMENT, L.P. purchased $4.6M of ARTV (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. purchased 531,326 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $8.66 ($8.57–$8.99, $4.60M total) across 3 trades over 2026-06-12 to 2026-06-16.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jun 16, 2026, 10:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Bullish
medium confidence
Mentioned
$ARTV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBullishLow
01

Why it matters

This provides a concrete, newly disclosed ownership change (size, price range, and post-transaction holdings) that may influence short-term sentiment, but it does not introduce new operational or financial information about Artiva.

02

Market read

Traders may monitor ARTV for sentiment follow-through, but the disclosure alone is unlikely to drive a durable repricing without accompanying fundamental catalysts.

03

What to watch

The trades were executed over several days and the filing notes no 10b5-1 plan; without context on prior intent or subsequent follow-through, signal strength is uncertain.

Relevance 7/10Novelty 6/10Timing: Filed 2026-06-16; trades occurred 2026-06-12 to 2026-06-16

Background

The article is an SEC Form 4 insider transaction disclosure: RA Capital Management (10% owner) bought Artiva Biotherapeutics shares in an open-market purchase.

Company-level read

Ticker impact

$ARTVBullishMedium confidence
Context

RA Capital Management, a 10% owner, reported an open-market purchase of 531,326 Artiva Biotherapeutics shares for ~$4.6M via SEC Form 4.

Expected impact

Near-term impact likely limited; any effect would be sentiment-driven and may fade unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source Form 4 showing size and timing, but it lacks new company fundamentals (no trial, approval, or guidance change).

Market effects

No sector-wide implication; this is a single-company ownership transaction.

None indicated.

None indicated.

Counterpoint

Form 4 buying by a large holder can reflect portfolio rebalancing, liquidity needs, or non-informational motives rather than a change in outlook.

Key entities

  • Artiva Biotherapeutics, Inc.

    Subject of the Form 4; received open-market purchases reported by RA Capital Management.

  • RA Capital Management, L.P.

    Reported indirect open-market purchases totaling ~$4.6M across three trades (2026-06-12 to 2026-06-16).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARTVMed

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a